Indian Journal of Medicine and Healthcare

Open Access Open Access  Restricted Access Subscription Access

The Transmission, Virulence and Etiology of an Epidemic Ailment "Plague" - A Crucial Review


Affiliations
1 Prist University, Department of Biotechnology, Puducherry Campus, Puducherry, India
2 Surya School of Pharmacy, Vikravandi, Villupuram, Tamilnadu, India
3 Kamalaktchi pandurangan College of Pharmacy, Thiruvannamalai, Tamilnadu, India
 

Plague is often fatal with out prompt and appropriate treatment. It affects mainly poor and remote populations. Late diagnosis is one of the major causes of human death and spread of the disease, since it limits the effectiveness of control measures. There are currently no approved vaccines for protection against this organism. The current U.S. Department of Defense candidate plague vaccine is a fusion between two Yersinia pestis. Also the protein recombinant models by which the proteins significantly augmented the IgG antibody response to the plague vaccine increased the probability of survival in murine models of plague. However, the attenuated plague vaccine still caused a high rate of severe local and systemic reactions in humans. Now, Rapid diagnostic tests (RDTs) for infectious diseases are of much value in facilitation of major improvements in disease management, especially in developing countries. The integration of the recombinant DNA into the nuclear genome of the plant cell is the most widely used strategy for production of plant-made Vaccine. Plant-made vaccine antigens can be delivered to a mucosal surface. Mucosal surfaces lining the digestive tract, respiratory tract and genitourinary tract are the most important portals of entry for mammalian pathogens. Thus, focus on plant-made vaccine against Y.pestis would lead us for approved vaccine development and plague management.

Keywords

Plague, Yersinia pestis, Epidemiology, Bio-terrorism, Vaccine.
User
Notifications

  • Achtman M, Zurth K, Morelli G, Torrea G, Guiyoule A and Carniel E (1999) Yersinia pestis, the cause of plague, is a recently emerged clone of Yersinia pseudotuberculosis. Proc. Natl. Acad. Sci. USA. 96, 14043–14048.

  • Adamovicz JJ and Andrews GP (2005) Plague vaccines. In: Lindler LE, Lebeda FJ, Korch GW, editors. Biological weapons defense: infectious diseases and counterbioterrorism. Totowa, New Jersey: Humana Press. pp: 121–153.

  • Amedeo Amedei et al. (2011) Role of immune response in Yersinia pestis infection, Accepted 23 May 2011, J. Infect .Dev. Courtries. 5(9), 628-639.

  • Baker EE, Sommer H, Foster LE, Meyer E and Meyer KF (1952) Studies on immunization against plague. 1. The isolation and characterization of the soluble antigen of Pasteurella pestis. J. Immunol. 68,131-145.

  • Chanteau S, Ratsifasoamanana L, Rasoamanana B et al. (1998) Plague, a reemerging disease in Madagascar. Emerg. Infect. Dis. 4, 101–104.

  • Christakos et al (2007) Recent results on the spatiotemporal modeling and comparative analysis of black death and bubonic plague epidemics. J. royal institute of public health. Public Health. 121, 700 – 720.

  • Cooper CL, Davis HL, Morris ML, Efler SM, Al Adhami M, Krieg AM, et al. CpG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a doubleblind phase I/II study. J. Clin. Immunol.24, 693–701.

  • Crook LD and Tempest B (1992) Plague - a clinical review of 27 cases. Arch. Int. Med. 152, 1253-1256. Kei Amemiya et al (2009) CpG oligodeoxynucleotides augment the murine immune response to the Yersinia pestis F1-V vaccine in bubonic and pneumonic models of plague. Vac. 27, 2220-2229.

  • Dongsheng Zhou et al (2006) Molecular and physiological insights into plague transmission, virulence and etiology. Microbes and Infection 8 (2006) 273–284.

  • Galimand M, Guiyoule A and Gerbaud G et al (1997) Multidrug resistance in Yersina pestis mediated by a transferable plasmid. N. Engl. J. Med. 37,667-680.

  • Galimand M, Guiyoule A, Gerbaud G, Rasoamanana B, Chanteau S, Carniel E and Courvalin P (1997) Multidrug resistance in Yersinia pestis mediated by a transferable plasmid. N. Engl. J. Med. 337,677–680.

  • Harris S (1992) Japanese biological warfare research on humans: a case study of microbiology and ethics. Ann. NY. Acad. Sci. 555, 21–52.

  • Heath DG, Anderson GWJ, Mauro JM, Welkos SL, Andrews GP, Adamovicz J, et al (1998) Protection against experimental bubonic and pneumonic plague by a recombinant capsular F1–V antigen fusion protein vaccine. Vac. 16,1131–1137.

  • Hinnebusch BJ, Perry RD and Schwan TG (1996) Role of the Yersinia pestis hemin storage (hms) locus in the transmission of plague by fleas. Sci. 273, 367– 370.

  • Jehangir S Sorabjee (2005)” Plague “is Consultant Physician at the Bombay Hospital Institute of Medical Sciences, Mumbai, India. Conflicts of interest: none declared. “Bacterial tropical infection”. The Medicine Publishing Company Ltd. pp: 30 -31.

  • Kapusta J, Modelska A, Figlerowicz M, Pniewski T, Letellier M and Lisowa O (1999) A plant-derived edible vaccine against hepatitis B virus. FASEB J. 13, 1796–1799.

  • Lillard JW Jr, Fetherston JD, Pedersen L, Pendrak ML and Perry RD (1997) Sequence and genetic analysis of the hemin storage (hms) system of Yersinia pestis. Gene. 193, 13–21.

  • Lucrecia Alvarez M (2006) Plant-made subunit vaccine against pneumonic and bubonic plague is orally immunogenic in mice. Vac. 24 , 2477–2490.

  • Lucrecia Alvarez M et al (2010) Prevention of bubonic and pneumonic plague using plant-derived vaccines. Biotechnology Adv. 28, 184-196.

  • Naktin J and Beavis KG (1999) Yersinia enterocolitica and Yersinia pseudotuberculosis. Clin. Lab. Med. 19 , 523–536 (vi).

  • Perry RD and Fertherston JD (1997) Yersinia pestis, etiologic agent of plague. Clin. Microbiol. Rev .10, 35- 66. The World Health Organization (2003) Outbreak news. Wkly Epidemiol. Rec. 75, 337–344.

  • Richard W and Titball et al (2001) Vaccination against bubonic and pneumonic plague. www.elsevier.com/locate/vaccine. Vac. 19, 4175– 4184.

  • Russell P, Eley SM, Hibbs SE, Manchee RJ, Stagg AJ and Titball RW (1995) A comparison of plague vaccine, USP and EV76 vaccine induced protection against Yersinia pestis in a murine model.Vac.13,1551–1556.

  • Smego RA, Frean J, Koornhof HJ and Yersiniosis I (1999) Microbiological and clinicoepidemiological aspects of plague and non-plague Yersinia infections. Eur. J. Clin. Microbiol. Infect. Dis. 18, 1–15.

  • Suzanne Chanteau et al (2003) Development and testing of a rapid diagnostic test for bubonic and pneumonic plague. 361, Pp: 211-216. www.thelancet.com

  • Tacket C, Mason H, Losonsky G, Clements J, Levine M and Arntzen Ch (1998) Immunogenicity in humans of a recombinant bacterial antigen delivered in a transgenic potato. Nat .Med. 4, 607–609.

  • Tacket C, Mason H, Losonsky G, Estes M, Levine M and Arntzen C (2000) Human immune responses to a novel Norwalk virus vaccine delivered in transgenic potatoes. J . Infect. Dis. 182, 302–305.

  • Thanavala Y, Mahoney M, Pal S, Scott A, Richter L, Natarajan N, et al.(2005) Immunogenicity in humans of an edible vaccine for hepatitis B. Proc. Natl. Acad. Sci. USA. 102, 3378–3382.

  • Titball RW and Williamson ED (2004) Yersinia pestis (plague) vaccines. Expert. Opin. Biol. Ther. 4(6), 965- 973.

  • Varthelyi D and Klinman DM (2003) Immunoregulatory activity of CpG oligonucleotides in humans and nonhuman primates. Clin. Immunol.109, 64–71.

  • Wren BW (2003) The yersiniae-a model genus to study the rapid evolution of bacterial pathogens. Nat. Rev. Microbiol. 1, 55–64.


Abstract Views: 418

PDF Views: 300




  • The Transmission, Virulence and Etiology of an Epidemic Ailment "Plague" - A Crucial Review

Abstract Views: 418  |  PDF Views: 300

Authors

Senguttuvan Sivan Mozhi
Prist University, Department of Biotechnology, Puducherry Campus, Puducherry, India
Vaikumdam Kannabirran
Surya School of Pharmacy, Vikravandi, Villupuram, Tamilnadu, India
Subramanian Madhu
Kamalaktchi pandurangan College of Pharmacy, Thiruvannamalai, Tamilnadu, India
R. Uthaya
Prist University, Department of Biotechnology, Puducherry Campus, Puducherry, India

Abstract


Plague is often fatal with out prompt and appropriate treatment. It affects mainly poor and remote populations. Late diagnosis is one of the major causes of human death and spread of the disease, since it limits the effectiveness of control measures. There are currently no approved vaccines for protection against this organism. The current U.S. Department of Defense candidate plague vaccine is a fusion between two Yersinia pestis. Also the protein recombinant models by which the proteins significantly augmented the IgG antibody response to the plague vaccine increased the probability of survival in murine models of plague. However, the attenuated plague vaccine still caused a high rate of severe local and systemic reactions in humans. Now, Rapid diagnostic tests (RDTs) for infectious diseases are of much value in facilitation of major improvements in disease management, especially in developing countries. The integration of the recombinant DNA into the nuclear genome of the plant cell is the most widely used strategy for production of plant-made Vaccine. Plant-made vaccine antigens can be delivered to a mucosal surface. Mucosal surfaces lining the digestive tract, respiratory tract and genitourinary tract are the most important portals of entry for mammalian pathogens. Thus, focus on plant-made vaccine against Y.pestis would lead us for approved vaccine development and plague management.

Keywords


Plague, Yersinia pestis, Epidemiology, Bio-terrorism, Vaccine.

References